Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

4 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

175%

7 of 4 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

N/A

4(50.0%)

Phase 1

2(25.0%)

Phase 2

1(12.5%)

Early Phase 1

1(12.5%)

8Total

N/A(4)

Phase 1(2)

Phase 2(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03329404Not ApplicableTerminated

Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood in Patients Requiring Chronic Transfusion (PRAISE)

Role: lead

NCT02964325Not ApplicableTerminated

Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia

Role: lead

NCT00742001Phase 1Terminated

Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival

Role: lead

NCT02330081Not ApplicableCompleted

Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood

Role: lead

NCT02118428Not ApplicableCompleted

Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria

Role: lead

NCT01368211Phase 2Terminated

Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)

Role: lead

NCT01907906Phase 1Completed

Inactivation of Whole Blood With Mirasol

Role: lead

NCT00263809Early Phase 1Completed

Safety and Performance of MIRASOL® PRT Treated Platelet Transfusion Products

Role: lead

All 8 trials loaded